QTTB (Q32 Bio) PE Ratio: 4.60 (As of Jul. 07, 2026) — 121% Above Median


QTTB Q32 Bio Inc QTTB
17 GF Score
Price $12.84
! 6 Warning Signs
View Full Analysis

What is Q32 Bio PE Ratio?

Q32 Bio QTTB -1.72% 17 PE Ratio is 4.60 as of Jul. 07, 2026, which is 121% above its 10-year median of 2.08. GuruFocus rates QTTB with a GF Score™ of 17/100. The stock has 6 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-07), Q32 Bio's share price is $12.84. Q32 Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $2.79. Therefore, Q32 Bio's PE Ratio for today is 4.60.

Warning Sign:

Q32 Bio Inc stock PE Ratio (=4.71) is close to 1-year high of 4.72.

During the past 5 years, Q32 Bio's highest PE Ratio was 4.91. The lowest was 1.42. And the median was 2.08.

Q32 Bio's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.54. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $2.79.

As of today (2026-07-07), Q32 Bio's share price is $12.84. Q32 Bio's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $2.79. Therefore, Q32 Bio's PE Ratio without NRI ratio for today is 4.60.

During the past 5 years, Q32 Bio's highest PE Ratio without NRI was 4.91. The lowest was 1.42. And the median was 2.08.

Q32 Bio's EPS without NRI for the three months ended in Mar. 2026 was $-0.54. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $2.79.

During the past 5 years, Q32 Bio's highest 3-Year average EPS without NRI Growth Rate was -35.40% per year. The lowest was -35.40% per year. And the median was -35.40% per year.

Q32 Bio's EPS (Basic) for the three months ended in Mar. 2026 was $-0.54. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $2.79.

Back to Basics: PE Ratio


Q32 Bio  (NAS:QTTB) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Q32 Bio PE Ratio Related Terms


Q32 Bio PE Ratio Historical Data

* Premium members only.

The historical data trend for Q32 Bio's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio PE Ratio Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
N/A N/A N/A At Loss 1.37

Q32 Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss 1.37 2.30

QTTB vs CAMP, CDXS, KROS: PE Ratio Comparison

For the Biotechnology subindustry, Q32 Bio's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q32 Bio PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's PE Ratio distribution charts can be found below:

* The bar in red indicates where Q32 Bio's PE Ratio falls into.


QTTB
17GF Score
Q32 Bio Inc QTTB
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q32 Bio PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Q32 Bio's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=12.84/2.790
=4.6

Q32 Bio's Share Price of today is $12.84.
Q32 Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.79.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 4.60 mean?
Q32 Bio (QTTB) has a PE Ratio of 4.60 as of Jul. 07, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Q32 Bio and its competitors. This is 121% above median its historical median of 2.08. Over the past decade, Q32 Bio's PE Ratio has ranged from 1.42 to 4.91.
Is Q32 Bio's PE Ratio too high?
Q32 Bio's current PE Ratio of 4.60 is 121% above median its 10-year median of 2.08. Over the past 10 years, this metric has ranged from a low of 1.42 to a high of 4.91. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's PE Ratio compare to CAMP and CDXS?
Q32 Bio's PE Ratio of 4.60 can be compared against companies in the Biotechnology industry. Historically, Q32 Bio's own PE Ratio has ranged from 1.42 to 4.91 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Biotechnology company?
A good PE Ratio depends on the Biotechnology industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Q32 Bio and its competitors. Q32 Bio's current PE Ratio is 4.60, which is 121% above median its own 10-year median of 2.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (QTTB) has a current PE Ratio of 4.60. The current PE Ratio is 4.60, which is 121% above median its 10-year median of 2.08. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Q32 Bio (QTTB), the current PE Ratio is 4.60 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q32 Bio Business Description

Other Exchanges DB0:Germany
Address 830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score

Get the complete analysis for QTTB

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.84
Price